We analyzed developmental expression of myotilin, a novel sarcomeric component mutated in limb-girdle muscular dystrophy 1A (LGMD1A). In situ hybridization and immunostaining of embryonic mouse tissues revealed expression of myotilin initially (E9±10) in heart, somites and neuroepithelium. At E13 myotilin was expressed in a variety of tissues, including the nervous system, lung, liver and kidney, but upon organ differentiation expression became more restricted. The level of expression during early development is comparable between mouse and human, indicating that the mouse may provide a model for further studying the functions of myotilin and the pathogenesis of LGMD1A. q
Results
Limb-girdle muscular dystrophy 1A (LGMD1A) is an autosomal dominant disease characterized by proximal limb weakness (Bartoloni et al., 1998) . Genetic analysis revealed a missense mutation in a novel gene, myotilin (Hauser et al., 2000) , encoding for a structural component of sarcomeric Z-discs and sarcolemma in human skeletal and cardiac muscle (Salmikangas et al., 1999) . Myotilin contains two immunoglobulin-like domains homologous to titin and a unique serine-rich N-terminal domain. It forms homodimers and binds to a-actinin, actin (Salmikangas et al., in preparation) and g-®lamin (van der Ven et al., 2000) . Myotilin is highly conserved between human and mouse (GeneBank AF230979).
Expression of myotilin during mouse development
We studied myotilin expression during mouse embryonic development by in situ hybridization (Figs. 1 and 2) and immunohistochemistry (Fig. 3) . Sections from embryonic day 8 (E8) to E17 were analyzed with two myotilin riboprobes or with an anti-myotilin antibody (Salmikangas et al., 1999) , that recognizes both human and mouse myotilin. Antisense probes showed an identical hybridization pattern, whereas no signal was detected with sense probes. Before day 9, no myotilin transcript was detected in the embryo. At E9 myotilin was clearly visible in the heart, the ®rst functional organ in vertebrate embryos (Fig. 1a,b) . Myotilin signal was also found in the yolk sac epithelium (not shown). At E10 and E11, myotilin mRNA ( Fig. 1g) and protein ( Fig. 3b) were found in the somites. Interestingly, while strong hybridization was obtained in the myotome, a weaker signal was also detected in the surrounding tissue (Fig. 1g) . Somitic expression of myotilin appears to be somewhat delayed in comparison to other sarcomeric proteins, which are usually detected at E9, before being aligned into mature myo®brils (Fu Èrst et al., 1989) . Myotilin was also present in the neural epithelium, in the heart, the primordium of the liver and the gut epithelium (Figs. 1e±h and 3d,f). Finally, a positive signal was also detected in the mesonephric tubules and the lung buds (data not shown).
At E13 (Figs. 2a±e and 3h,j), myotilin mRNA and protein were found in many developing tissues, including muscles, lungs, liver and developing cartilage primordia of the ribs. In the nervous system, myotilin was expressed in the cells lining the spinal canal ( Fig. 2e ) and the encephalic ventricles ( Fig. 2c) , in cervical and spinal root ganglia (Figs. 2d and 3j) and the choroid plexus (not shown). Moreover, myotilin probes hybridized with the heart, the intestinal epithelium and that of urogenital structures, such as tubules of metanephros and regressing mesonephros. Immunohistochemical analysis con®rmed myotilin expression in the tissues, where transcription was active. At E16 (Fig. 2f±i) , myotilin synthesis became more restricted, as only striated muscles and peripheral neurons maintained a high level of expression (Fig. 2h,i) . In the liver and especially in the lungs, in which at this stage extensive branching of the bronchial tree takes place, expression was signi®cantly decreased, except for the bronchial epithelium (Fig. 2g) . In the developing bones, the signal accumulated at the perichondrium (Fig. 2h) . Skin epidermis showed strong staining (Figs. 2f and 3l) , while dermis, which originates from the somitic dermatome, was negative. Thyroid and parathyroid glands also showed myotilin expression at this stage (not shown).
These experiments show that myotilin is expressed in a variety of tissues during mouse embryogenesis and the level of expression reaches a peak around E13 and then decreases (Table 1) . Overall, myotilin is more widespread in the embryo than in the adult mouse. This suggests a role for myotilin in tissue modeling, in line with its proposed involvement in the organization of the actin-based cytoskeleton (van der Ven et al., 2000) . A similar downregulation was described for b-sarcoglycan (Fougerousse et al., 1998) , a sarcolemmal protein, and palladin (Parast and Otey, 2000) , a cytoskeletal protein homologous to myotilin.
Embryonic expression of human myotilin
Because developmental expression of mouse myotilin appeared not to be restricted to the muscle lineage, we asked whether a similar pattern is observed in human. Fig.  4 shows a comparison between myotilin and titin, another sarcomeric protein, in human embryos at 3±4 gestational weeks. While titin was detected only in the myotomal compartment of the somites (Fig. 4e,f) , myotilin was present in a broader area including the dermatome, the neural tube epithelium (Fig. 4c,d ), and less intensively in the surrounding mesoderm and the surface ectoderm. Thus, also in human embryos, myotilin expression is not restricted to muscle cells. A similar expression pattern in early embryonic development and comparable Northern blot data of adult tissues (Mologni et al., in preparation) suggest that transcriptional regulation of human and mouse myotilin is conserved. Therefore, the generation of mouse genetic models should provide relevant information on the role of myotilin in development and muscular dystrophy.
Methods

In situ hybridization
Sense and antisense digoxygenin-labeled riboprobes were synthesized from two regions of myotilin cDNA (nt 531± 1056 and nt 1614±2150) by in vitro transcription. The experiments were approved by the Animal Welfare Committee of the University of Helsinki. Embryos were ®xed in 4% paraformaldehyde, dehydrated in ethanol and xylene and embedded in paraf®n. Four micrometer sections were placed on glass slides and treated as described (Ponassi et al., 1999) .
Immunohistochemistry
Mouse specimens were frozen in isopentane and stored at 2808C until used. Human embryos were obtained from legal abortions induced by Mifepristone (RU486) at Hopital Broussais in Paris. All procedures were approved by the Ethical Committee in Paris. Tissues were frozen in dry ice and stored at 2808C until used. Seven micrometer cryostat sections were mounted on slides, air-dried and stored at a Embryonic (E) days are shown in the ®rst column. The various anatomical structures in the top row include respective precursors (e.g. somites for skeletal muscles, mesonephros for kidneys and cartilaginous condensations for the skeleton). CNS, central nervous system; PNS, peripheral nervous system. ND, not determined. Level of expression is reported as absent (2), very low (^), low (1), medium (1 1 ) or high (111).
b Adult data from Mologni et al., in preparation. 2808C. Sections were immunostained using af®nity-puri®ed myotilin antiserum (Salmikangas et al., 1999) and titin-speci®c monoclonal antibody (Fougerousse et al., 1998) .
